Objective: To determine the effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in patients with non-small cell lung cancer.
Method: This is a retrospective observational study including patients treated in second line and beyond. The effectiveness of treatment was assessed by means of overall survival and progression free survival measurements.